SCHEMBL2582625

SCHEMBL2582625

Cc1cc(-c2nc3ccccc3c(=O)n2-c2ccc(N)cc2)cc(C)c1OCCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.46
NPSR1 Q6W5P4 2/20 0.44
RAB9A P51151 1/20 0.44
KCNH2 Q12809 2/20 0.43
HRH3 Q9Y5N1 2/20 0.43
LMNA P02545 3/20 0.43
MAPK1 P28482 1/20 0.43
G6PD P11413 1/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HSP90AA1 P07900 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AKT1 P31749 1/20 0.41
ADRA1A P35348 1/20 0.41
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
NPY1R P25929 1/20 0.39
NPY2R P49146 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2563227 0.88 ALDH1A1 (0.45) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL2564148 0.87 ALDH1A1 (0.51) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL2577765 0.80 MAPT (0.52) ALDH1A1NPSR1RAB9AMAPK1MAPT
SCHEMBL2562510 0.79 ALDH1A1 (0.49) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL15361558 0.79 ALDH1A1 (0.43) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL2565762 0.77 ALDH1A1 (0.49) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL2567691 0.77 ALDH1A1 (0.49) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL15361427 0.77 G6PD (0.36) ALDH1A1HRH3LMNAMAPK1G6PD
SCHEMBL2562815 0.77 ALDH1A1 (0.51) ALDH1A1NPSR1RAB9AKCNH2HRH3
SCHEMBL2566454 0.77 ALDH1A1 (0.51) ALDH1A1NPSR1RAB9AKCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2660238-B1 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP (CA) 2015-05-06 EP disclosed
US-8952021-B2 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP. (CA) 2015-02-10 US disclosed
EP-2382194-B1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP (CA) 2014-03-12 EP disclosed
EP-2660238-A1 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP. (CA) 2013-11-06 EP disclosed
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-12-01 US disclosed
EP-2382194-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-11-02 EP disclosed
WO-2010079431-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE APOB, APOL1, LDLR ALDH1A1 355/4885NPSR1 2570/4885RAB9A 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.